FibroGen (NASDAQ: FGEN) reported Q3 EPS of ($0.50), $0.15 worse than the analyst estimate of ($0.35). Revenue for the quarter came in at $29.03 million versus the consensus estimate of $36.48 million.

For earnings history and earnings-related data on FibroGen (FGEN) click here.